{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:18:16Z","timestamp":1782793096094,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.maturitas.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T15:48:01Z","timestamp":1358351281000},"page":"220-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Ospemifene, vulvovaginal atrophy, and breast cancer"],"prefix":"10.1016","volume":"74","author":[{"given":"Gregory T.","family":"Wurz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin H.","family":"Soe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"DeGregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.maturitas.2012.12.002_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/eog.11.3","article-title":"Current treatment options for vulvovaginal atrophy","volume":"6","author":"Burich","year":"2011","journal-title":"Expert Review of Obstetrics & Gynecology"},{"key":"10.1016\/j.maturitas.2012.12.002_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/PPA.S22943","article-title":"Update on alternative therapies for vulvovaginal atrophy","volume":"5","author":"Chollet","year":"2011","journal-title":"Patient Preference and Adherence"},{"issue":"8","key":"10.1016\/j.maturitas.2012.12.002_bib0015","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","article-title":"Risk of menopause during the first year after breast cancer diagnosis","volume":"17","author":"Goodwin","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1016\/j.maturitas.2012.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1016\/j.maturitas.2012.12.002_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1470-2045(05)70316-8","article-title":"Management of menopausal symptoms in patients with breast cancer: an evidence-based approach","volume":"6","author":"Hickey","year":"2005","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"issue":"18","key":"10.1016\/j.maturitas.2012.12.002_bib0035","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"Journal of the National Cancer Institute"},{"issue":"23","key":"10.1016\/j.maturitas.2012.12.002_bib0040","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"Journal of the American Medical Association"},{"issue":"6652","key":"10.1016\/j.maturitas.2012.12.002_bib0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.maturitas.2012.12.002_bib0050","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/jm020449y","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions","volume":"46","author":"Jordan","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1\u20132","key":"10.1016\/j.maturitas.2012.12.002_bib0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.mrfmmm.2005.02.028","article-title":"Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance","volume":"591","author":"Lewis","year":"2005","journal-title":"Mutation Research"},{"issue":"5","key":"10.1016\/j.maturitas.2012.12.002_bib0060","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/jcb.20820","article-title":"Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells","volume":"98","author":"Scafoglio","year":"2006","journal-title":"Journal of Cellular Biochemistry"},{"issue":"7","key":"10.1016\/j.maturitas.2012.12.002_bib0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.maturitas.2012.12.002_bib0070","first-page":"359","article-title":"Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism","volume":"9","author":"Shiau","year":"2002","journal-title":"Natural Structural Biology"},{"issue":"1","key":"10.1016\/j.maturitas.2012.12.002_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/er.2003-0023","article-title":"Coregulator function: a key to understanding tissue specificity of selective receptor modulators","volume":"25","author":"Smith","year":"2004","journal-title":"Endocrine Reviews"},{"issue":"5564","key":"10.1016\/j.maturitas.2012.12.002_bib0080","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"issue":"39","key":"10.1016\/j.maturitas.2012.12.002_bib0085","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1204729","article-title":"Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells","volume":"20","author":"Marquez","year":"2001","journal-title":"Oncogene"},{"issue":"1\u20132","key":"10.1016\/j.maturitas.2012.12.002_bib0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0303-7207(01)00526-3","article-title":"Differential cellular localization of estrogen receptor alpha in uterine and mammary cells","volume":"181","author":"Monje","year":"2001","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"1","key":"10.1016\/j.maturitas.2012.12.002_bib0095","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/bcr959","article-title":"Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1\/2 activation in MCF-7 cells","volume":"7","author":"Zivadinovic","year":"2005","journal-title":"Breast Cancer Research"},{"issue":"5715","key":"10.1016\/j.maturitas.2012.12.002_bib0100","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","article-title":"A transmembrane intracellular estrogen receptor mediates rapid cell signaling","volume":"307","author":"Revankar","year":"2005","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.maturitas.2012.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1211\/0022357022089","article-title":"Non-genomic effects of tamoxifen on the activation of membrane-bound guanylate cyclase GC-A","volume":"55","author":"Chen","year":"2003","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1677\/jme.1.01784","article-title":"Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells","volume":"35","author":"Horner-Glister","year":"2005","journal-title":"Journal of Molecular Endocrinology"},{"issue":"5","key":"10.1016\/j.maturitas.2012.12.002_bib0115","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jcp.22461","article-title":"Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor alpha and beta","volume":"226","author":"Rossi","year":"2011","journal-title":"Journal of Cellular Physiology"},{"issue":"19","key":"10.1016\/j.maturitas.2012.12.002_bib0120","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","article-title":"Tamoxifen therapy for breast cancer and endometrial cancer risk","volume":"91","author":"Bernstein","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1016\/j.maturitas.2012.12.002_bib0125","first-page":"61","article-title":"Clinical targets of investigational selective estrogen receptor modulators: current status and development","volume":"9","author":"Wurz","year":"2005","journal-title":"Current Topics in Pharmacology"},{"issue":"2","key":"10.1016\/j.maturitas.2012.12.002_bib0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.maturitas.2012.12.002_bib0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.maturitas.2012.12.002_bib0145","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.maturitas.2012.12.002_bib0150","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"issue":"4\u20135","key":"10.1016\/j.maturitas.2012.12.002_bib0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jsbmb.2005.06.027","article-title":"Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice","volume":"97","author":"Wurz","year":"2005","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"6","key":"10.1016\/j.maturitas.2012.12.002_bib0165","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/019262301753386031","article-title":"Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator","volume":"29","author":"Long","year":"2001","journal-title":"Toxicologic Pathology"},{"issue":"2","key":"10.1016\/j.maturitas.2012.12.002_bib0170","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1006\/gyno.2001.6578","article-title":"The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women","volume":"85","author":"Neven","year":"2002","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1016\/j.maturitas.2012.12.002_bib0175","doi-asserted-by":"crossref","first-page":"R881","DOI":"10.1186\/bcr1317","article-title":"Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ","volume":"7","author":"Namba","year":"2005","journal-title":"Breast Cancer Research"},{"issue":"8","key":"10.1016\/j.maturitas.2012.12.002_bib0180","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1158\/1535-7163.941.3.8","article-title":"Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes","volume":"3","author":"Maglione","year":"2004","journal-title":"Molecular Cancer Therapeutics"},{"issue":"22","key":"10.1016\/j.maturitas.2012.12.002_bib0185","first-page":"8298","article-title":"Transgenic polyoma middle-T mice model premalignant mammary disease","volume":"61","author":"Maglione","year":"2001","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.maturitas.2012.12.002_bib0190","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0002-9440(10)63568-7","article-title":"Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases","volume":"163","author":"Lin","year":"2003","journal-title":"American Journal of Pathology"},{"issue":"1","key":"10.1016\/j.maturitas.2012.12.002_bib0195","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/gme.0b013e318223e82a","article-title":"Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model","volume":"19","author":"Burich","year":"2012","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0200","first-page":"954","article-title":"Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease","volume":"12","author":"Guy","year":"1992","journal-title":"Molecular and Cellular Biology"},{"issue":"6\u20137","key":"10.1016\/j.maturitas.2012.12.002_bib0205","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002280000176","article-title":"Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator","volume":"56","author":"DeGregorio","year":"2000","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB Journal"},{"issue":"4","key":"10.1016\/j.maturitas.2012.12.002_bib0215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi","year":"2006","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"3","key":"10.1016\/j.maturitas.2012.12.002_bib0220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women","volume":"18","author":"Komi","year":"2004","journal-title":"Gynecological Endocrinology"},{"issue":"5","key":"10.1016\/j.maturitas.2012.12.002_bib0225","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.GME.0000063566.84134.98","article-title":"Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women","volume":"10","author":"Ylikorkala","year":"2003","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.maturitas.2012.12.002_bib0230","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/17425255.2010.487483","article-title":"Pharmacologic evaluation of ospemifene","volume":"6","author":"McCall","year":"2010","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512212004021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512212004021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:56:17Z","timestamp":1759913777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512212004021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0378512212004021"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2012.12.002","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ospemifene, vulvovaginal atrophy, and breast cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2012.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}